Glaxo/Innoviva's Trelegy Ellipta Gets Line Extension In Europe
Zacks Investment Research | Nov 12, 2018 09:22PM ET
GlaxoSmithKline plc (NYSE:GSK) and partner Innoviva, Inc. (NASDAQ:INVA) announced the approval of label expansion of chronic obstructive pulmonary disease (“COPD”) drug, Trelegy Ellipta, in Europe. The drug is now approved as a maintenance treatment in a broader moderate-to-severe COPD patient population those who are not adequately treated by a long-acting muscarinic antagonist (“LAMA”) and long-acting beta2-agonist (“LABA”) or dual bronchodilation.
Trelegy Ellipta, a triple combination therapy of inhaled corticosteroid (“ICS”)/LAMA/LABA (fluticasone furoate/umeclidinium/vilanterol 'FF/UMEC/VI'), is already approved as maintenance treatment for COPD patients who are not adequately treated by a combination of ICS and a LABA.
The label expansion was approved based on data from phase III IMPACT study, which showed that the closed triple combination, Trelegy Ellipta, is superior to ICS-LABA combination, Relvar/Breo Ellipta, and LAMA-LABA combination, Anoro Ellipta, in improving lung function and health-related quality of life, and reducing exacerbations in COPD patients. A similar label update was approved by the FDA in April.
GlaxoSmithKline’s shares have gained 15.7% so far this year compared with 8% increase of the industry during the period.
Trelegy Ellipta brought in sales of £32 million in the United States and £9 million in the EU during the third quarter. Trelegy Ellipta benefited from share gains following FDA approval to include IMPACT data on the U.S. label. We expect further share gains following approval in Europe.
Please note that Theravance Biopharma, Inc. (NASDAQ:TBPH) has an economic interest on the royalties that Glaxo will pay to Innoviva on global sales of Trelegy Ellipta.
Glaxo has seen strong growth momentum in its three new products — Trelegy Ellipta, Shingrix and Juluca – so far this year. Moreover, the agreement to buy out Novartis’ (NYSE:NVS) stake in the Consumer Healthcare JV has strengthened Glaxo’s competitive position.
We remind investors that AstraZeneca is also developing a triple combination therapy PT010 for the treatment of COPD.
GlaxoSmithKline plc Price
Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.